Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil after aortic valve replacement for coronary microcirculation dysfunction
ChiCTR1900023816Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicorandil in Coronary Small Vessel Disease (CMD), heart failure (HF) and hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Improvement rate of peak rate of contrast agents in the same myocardial section and site. Started Jun 2019; status: recruiting.
02
Drugs
nicorandil
03
Conditions
Coronary Small Vessel Disease (CMD)heart failure (HF)hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on ChiCTR1900023816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023816.